QUICK LINKS

# For Further Reading

## Osimertinib in the First Line


- **Soria JC,** Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125.
- **Ramalingam SS,** Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41-50.


## EGFR/VEGF


- **Yu HA,** Schoenfeld AJ, Makhnin A, et al. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. JAMA Oncol. 2020;6(7):1048-1054.
- **Akamatsu H;** Toi TY, Hayashi H, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor. JAMA Oncol. Published online January 7, 2021. doi:10.1001/jamaoncol.2020.6758.
- **Nakagawa K,** Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655-1669.
- **Seto T,** Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236-1244.
- **Saito H,** Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019; 20(5):625-635.
- **Maemondo M,** Fukuhara T, Saito H, et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. J Clin Oncol. 2020;38(15 suppl):9506-9506.


## EGFR/Chemotherapy


- **Hosomi Y,** Morita S, Sugawara S, et al. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020;38(2):115-123.
- **Noronha V,** Patil VM, Joshi A, et al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol. 2020;38(2):124-136.

## Acquired Resistance to Osimertinib


- **Ramalingam SS,** Cheng Y, Zhou C, et al. 5005 - Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Presented at the European Society of Medical Oncology 2018 Congress; October 19, 2018.
- **Le X, Puri S,** Negrao MV, Nilsson MB, et al. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in *EGFR*-Mutant NSCLC. *Clin Cancer Res*. 2018;24(24):6195-6203.
- **Piotrowska Z,** Isozaki H, Lennerz JK, et al. Landscape of Acquired Resistance to Osimertinib in *EGFR*-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired *RET* Fusion. *Cancer Discov*. 2018; 8(12):1529-1539.
- **Schoenfeld AJ,** Chan JM, Kubota D, et al. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in *EGFR*-Mutant Lung Cancer. *Clin Cancer Res.* 2020; 26(11):2654-2663.


## EGFR/MET


- **Sequist LV,** Han J-Y, Ahn M-J, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. *Lancet Oncol.* 2020;21(3):373-386.
- **Wu YL, Cheng Y,** Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. *Lancet Respir Med.* 2020;8(11):1132-1143.
- **Wu Y-L,** Ahn M-J, Garassinno MC, et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). *J Clin Oncol.* 2018;36(26):2702-2709.
- **Haura EB,** Cho BC, Lee JS, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). *J Clin Oncol.* 2019;37(15 suppl): 9009-9009.


## Small Cell Transformation


- **Marcoux N,** Gettinger SN, O'Kane G, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. *J Clin Oncol.* 2019;37(4):278-285.
- **Lee JK,** Lee J, Kim S, et al. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. *J Clin Oncol.* 2017; 35(26):3065-3074.